GAGE2A Human

The GAGE2A gene is organized in clustered repeats and exhibits a high degree of sequence identity with other members of the GAGE family. However, it differs by scattered single nucleotide substitutions . The sequences of these genes contain either the antigenic peptide YYWPRPRRY or YRPRPRRY, which are recognized by cytotoxic T-cells .

The recombinant form of GAGE2A is produced in Escherichia coli (E. coli) and is a single, non-glycosylated polypeptide chain containing 139 amino acids (1-116) with a molecular mass of approximately 15.2 kDa . The recombinant protein is often fused to a 23 amino acid His-tag at the N-terminus to facilitate purification .

GAGE2A is predominantly expressed in various tumors, including melanoma, lung cancer, and breast cancer, among others . In normal tissues, its expression is limited to germ cells, such as those found in the testis . The restricted expression pattern in normal tissues and widespread expression in tumors make GAGE2A a potential target for cancer immunotherapy.

The antigenic peptides derived from GAGE2A can be presented on the surface of tumor cells by major histocompatibility complex (MHC) molecules. These peptides are recognized by cytotoxic T-cells, which can then target and destroy the tumor cells .

Recombinant GAGE2A protein is used in various research applications, including studies on cancer immunotherapy, tumor biology, and the development of cancer vaccines . The protein is typically purified using conventional chromatography techniques and is available in different formulations for laboratory research .

The recombinant GAGE2A protein should be stored at 4°C for short-term use and at -20°C for long-term storage. It is important to avoid multiple freeze-thaw cycles to maintain the protein’s stability and activity .